Heart monitoring during lung cancer therapy may save lives

NCT ID NCT04980716

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether early heart monitoring and medication can prevent heart problems in people with advanced lung cancer receiving chemoradiotherapy and immunotherapy. About 524 participants will be randomly assigned to receive either standard care or additional heart-focused treatment guided by a special monitoring device. The goal is to see if this approach improves survival and reduces heart-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cardiovascular drugs (Golden Triangle therapy)
What this could lead to: If successful, this approach could reduce heart complications and improve survival for lung cancer patients receiving aggressive cancer therapy.
What could go wrong: This is a large phase III trial, but the intervention is complex and may not significantly improve outcomes. Heart drugs also carry their own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR COMPLICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR COMPLICATION NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.